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Abstract: 
In this work, we evaluate the tissue response and tolerance to a designed 
3D porous scaffold composed of nano-carbonate-hydroxyapatite and 
agarose as a preliminary step in bone repair and regeneration. These 
scaffolds were subcutaneously implanted into rats, which were sacrificed at 
different times. CD4+, CD8+ and ED1+ cells were evaluated as 
measurements of inflammatory reaction and tolerance. We observed some 
inflammatory response early after subcutaneous implantation. The 3D 
interconnected porosity increased scaffold integration via the formation of 
granulation tissue and the generation of a fibrous capsule around the 
scaffold. The capsule is initially formed by collagen which progressively 
invades the scaffold, creating a network that supports the settlement of 
connective tissue and generating a compact structure. The timing of the 
appearance of CD4+ and CD8+ cell populations is in agreement with the 
resolved inflammatory response. The appearance of macrophage activity 
evidences a slow and gradual degradation activity. Degradation started 
with the agarose component of the scaffold, but the nano-apatite was kept 
intact for up to 30 days. Therefore, this apatite/agarose scaffold showed a 
high capacity for integration by a connective network that stabilizes the 
scaffold and results in slow nano-apatite degradation. The fundamental 
properties of the scaffold would provide mechanical support and facilitate 
bone mobilization, which is of great importance in the masticatory system 
or large bones. 
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In this work, we evaluate the tissue response and tolerance to a designed 3D porous 5 
scaffold composed of nano-carbonate-hydroxyapatite and agarose as a preliminary step 6 
in bone repair and regeneration. These scaffolds were subcutaneously implanted into 7 
rats, which were sacrificed at different times. CD4+, CD8+ and ED1+ cells were 8 
evaluated as measurements of inflammatory reaction and tolerance. We observed some 9 
inflammatory response early after subcutaneous implantation. The 3D interconnected 10 
porosity increased scaffold integration via the formation of granulation tissue and the 11 
generation of a fibrous capsule around the scaffold. The capsule is initially formed by 12 
collagen which progressively invades the scaffold, creating a network that supports the 13 
settlement of connective tissue and generating a compact structure. The timing of the 14 
appearance of CD4+ and CD8+ cell populations is in agreement with the resolved 15 
inflammatory response. The appearance of macrophage activity evidences a slow and 16 
gradual degradation activity. Degradation started with the agarose component of the 17 
scaffold, but the nano-apatite was kept intact for up to 30 days. Therefore, this 18 
apatite/agarose scaffold showed a high capacity for integration by a connective network 19 
that stabilizes the scaffold and results in slow nano-apatite degradation. The 20 
fundamental properties of the scaffold would provide mechanical support and facilitate 21 
bone mobilization, which is of great importance in the masticatory system or large 22 
bones. 23 
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Introduction 30 
In the United States, more than half a million patients per year receive bone defect 31 
replacements, costing more than 2.5 billion dollars [1]. Autologous bone is considered 32 
the gold standard due to its osteoinductive capacity, the presence of growth factors and 33 
osteogenic cells, and its excellent performance as a scaffold that facilitates the viability 34 
of osseous implants [2]. However, excessive morbidity, together with availability 35 
issues, compromises the use of autologous bone to a great extent. Therefore, allografts 36 
and xenografts are feasible alternatives to overcome these complications. However, the 37 
use of xenografts is less than ideal due to increased rejection rates and the increased risk 38 
of disease transmission due to the use of bovine osseous grafts [3, 4].  39 
Advancements in the development and compatibility of biomaterials are crucial 40 
milestones in the progress of tissue engineering and in particular of regenerative 41 
medicine. Improvements must especially be geared toward the utilization of 42 
biomaterials as substitutes and/or inductors in the repair of different tissues, such as 43 
bone. Several studies have demonstrated the validity of such biomaterials as bone 44 
substitutes that could decrease patient morbidity while utilizing the most remarkable 45 
advantages of autografts: mechanical strength, osteoinduction, osteoconduction and 46 
biodegradation [5, 6]. Moreover, to meet the objectives for which these biomaterials 47 
were designed, the biomaterials should be properly tolerated by the host organism [6, 7] 48 
to avoid long term side effects.   49 
The biomimetic approach, a growing strategy in th  biomaterials field, allows the 50 
fabrication of materials similar to natural ones, in terms of both composition and 51 
structure. For example, apatite, the inorganic component of bones, can be prepared 52 
using biomimetic patterning and is an ideal material for osseous regeneration [8]. 53 
Moreover, the combination of apatite with natural or synthetic polymers [9-11] deepens 54 
this approach and improves its performance. 55 
In this work, scaffolds containing agarose and a nano-carbonate-hydroxyapatite (nCHA) 56 
have been prepared by the GELPOR3D [12-14]. This shaping method allows for the 57 
preparation of scaffolds that can be described as ceramic reinforced hydrogels. The 58 
structural components maintain both their original microstructural and textural 59 
properties and thus their original functionality. The ceramic component, apatite crystals 60 
of the same order of magnitude as those found in natural bone, facilitates the generation 61 
of newly formed bone and improves the mechanical properties of the scaffolds as well 62 
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as their handling [15, 16]. The apatite ceramic is embedded in an agarose hydrogel, a 63 
three-dimensional polysaccharide matrix that resembles an extracellular matrix where 64 
water is the main component. In addition to its many different uses within the 65 
biotechnology field [17, 18]
,
 agarose is used in the biomaterial field as a matrix to 66 
regenerate damaged tissue. It has also been used as a component of a device for 67 
controlled drug release. Therefore, agarose has been considered a potential candidate for 68 
the regeneration of different types of tissues, especially bone and cartilage [19-24], 69 
pancreas [25, 26] and nervous system tissues [27, 28]. Taken together, the combination 70 
of both apatite and agarose components constitutes a promising alternative in bone 71 
regeneration therapy. 72 
In addition, the possibility of tailoring the pore architecture to mimic that of natural 73 
bone tissue should facilitate tissue colonization. This could give rise to a compact 74 
composite that would be integrated with soft tissues but would progressively degrade. 75 
This would ensure the mechanical support and bone mobilization required in areas such 76 
as the masticatory apparatus or large bones. The overall objective of this study was to 77 
design a subcutaneous implant model to characterize the tissue tolerance of a designed 78 
3D interconnected porous scaffold composed of nano-carbonate-hydroxyapatite and 79 
agarose. 80 
Materials and methods 81 
Fabrication of a 3D macroporous scaffold  82 
The materials used in this work were generated with nanocrystalline carbonate- 83 
hydroxyapatite (nCHA), prepared using a precipitation method previously described 84 
elsewhere [29]
,
 and the polysaccharide agarose (purchased from Sigma-Aldrich). The 85 
macroporous nCHA/agarose scaffolds, in an 80/20 weight ratio, were fabricated with a 86 
porosity designed using the GELPOR3D method [12-14, 30]. Briefly, a translucent sol 87 
was prepared by heating an agarose/water suspension (2.5% wt/vol) at 85ºC; then, the 88 
temperature was progressively lowered to approximately 40–45ºC, and the nCHA 89 
particles were added under continuous stirring conditions. The obtained slurry was 90 
poured into the designed mold, where the suspension gelation process occurred at room 91 
temperature within a few minutes. At this point, the pieces were consistent enough to be 92 
extracted from the mold, handled and shaped into the desired form. In this study, 93 
cylinders 4 mm high and 10 mm in diameter were fabricated. The materials were frozen 94 
at -86°C for 24 h and dried in a Heto DRYWINNER lyophilizer for 24 h.  95 
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Ectopic implantation of scaffolds  96 
Female Wistar rats (n = 24) between 4-4.5 months of age and with a weight of 235 g ± 97 
15 g were used in this study. This study was carried out in accordance with the 98 
European Union guidelines for experimental animal housing and management. 99 
Before the nCHA/agarose biomaterials (4x10 mm) were subcutaneously implanted, they 100 
were sterilized using UV radiation for 30 min. The animals were anesthetized with an 101 
intraperitoneal injection of ketamine hydrochloride (IMALGENE® 1000 injectable, 102 
MERIAL LABORATORIOS, S.A. Barcelona. Spain) and Xilazine hydrochloride 103 
(Rompun, BAYER Barcelona. Spain). To create a pocket for the introduction of the 104 
biomaterial piece, a 2 cm incision was created in the skin that covered the dorsal 105 
muscle. Finally, the wound was sutured, and the scaffold was enclosed within the 106 
subcutaneous cellular tissue (Figure 1). The animals were sacrificed after 7, 14, 21 and 107 
30 days (6 rats per group) by means of an anesthetic overdose. Immediately after the 108 
sacrifice, the scaffolds were extracted and prepared for macro and microscopic 109 
characterization.  110 
Macroscopic characterization 111 
The wounds were clinically analyzed to detect the presence of edema, flushing, 112 
temperature increase, exudate, or any other evidence of inflammation or wound healing 113 
alterations. The morphologic characterizations of the implanted scaffolds and the 114 
surrounding tissues were performed on randomly selected sections of these areas. 115 
Histology and immunohistochemistry assays 116 
Samples were embedded in paraffin for histological and immunohistochemical studies. 117 
Sections (6-8 mm) were extracted from the samples and stained using conventional 118 
techniques (Hematoxylin-eosin and Sirius Red stainings for collagen type 119 
identification). 120 
The cytotoxicity and biocompatibility studies were performed using 121 
immunohistochemistry techniques for the identification of foreign body specific 122 
markers as well as the detection of inflammation. The presence of proinflammatory 123 
cells (CD4+ and CD8+ lymphocytes) and macrophage cells (ED1+) was determined 124 
using immunofluorescence techniques. These studies were performed with a Leica 125 
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TCS-SP5 laser confocal microscope using the phycoerythrin and DAPI fluorochromes 126 
as tracers to contrast nuclei. 127 
The scaffold angiogenic and osteoinduction capacities were determined using 128 
conventional immunohistochemistry techniques. Samples were stained with Vascular 129 
Endothelial Growth Factor (VEGF) to determine the angiogenic capacity of the scaffold 130 
and Osteopontin (OPN), Osteocalcin (OC), RunX2 and Tartrate Resistant Acid 131 
Phosphatase (TRAP) to determine the scaffold osteoinduction capacity. 132 
The following specific monoclonal antibodies were utilized in these assays: Anti-CD4 133 
(LabGen, Germany), 1:50 dilution; Anti-CD8 (LabGen, Germany), 1:50 dilution; Anti-134 
ED1 (Serotec, UK), 1:100 dilution; Anti-VEGF (ABCam, Cambridge, UK), 1:50 135 
dilution; anti-Osteopontin (Santa Cruz, Madrid, Spain), 1:50 dilution; anti-Osteocalcin 136 
(Santa Cruz, Madrid, Spain), 1:50 dilution; anti-RunX2 (Santa Cruz, Madrid, Spain), 137 
1:50 dilution and Anti-TRAP (Santa Cruz, Madrid, Spain), 1:50 dilution. 138 
Statistical Analysis 139 
GraphPad Prism® 5.1 program was used for the statistical analysis, applying the Mann 140 
Whitney U test. The significance is s t at p <0.05 (*), p <0.005 (**), p <0.001 (***). 141 
Results 142 
nCHA/agarose Scaffolds  143 
The nCHA/agarose scaffolds have been thoroughly characterized in previous studies 144 
[13, 14, 30]. The scaffold is macroscopically described as a reinforced hydrogel with a 145 
rubber-like texture that can be easily manipulated and shaped by hand by means of a 146 
simple cutter. This enables a perfect match of the scaffold into the bone defect. 147 
Furthermore, it was determined that the original microstructural characteristics of the 148 
nCHA (small size, 15–20 x 3–5 nm, and 8% carbonate content) are maintained after the 149 
scaffold fabrication.  150 
The obtained scaffolds displayed a 3D interconnected porosity constituted by “giant” 151 
pores approximately 800 µm in size (Figure 1 inset). This porosity was designed to 152 
facilitate implant vascularization and cell colonization. The scaffolds possessed a 153 
hierarchical pore architecture with additional pore distributions in the 100-200 µm and 154 
50-100 nm ranges that enabled cell migration and fluid exchange. The contribution of 155 
these graded pore distributions to the overall porosity, estimated to be approximately 156 
90-95%, could be quantified by means of He pycnometry and Hg intrusion porosimetry. 157 
Of the total porosity, 30 ± 0.1% corresponded to the designed giant pores (800 µm), 158 
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61.7 ± 0.1% of the porosity was attributed to pores between 100-200 µm generated as a 159 
consequence of the freeze-drying process, and the remaining 2.9 ± 0.1% of the porosity 160 
was from the pores between 50 and 100 nm that resulted from the spaces that exist 161 
between the apatite particles. 162 
The synthesized scaffolds behaved like hydrogel in that the network was able to absorb 163 
water or any fluid within its structure, swell without destruction, and maintain its 164 
overall architecture. While the overall shape did not change, a slight increase in the 165 
scaffold dimensions was observed during the swelling process. This could ensure an 166 
ideal fit between the scaffold and the osseous defect. 167 
Subcutaneous implants 168 
Seven days after implantation, the implant zone looked unremarkable and healthy with 169 
no evidence of edema or suppuration. This was indicative of a natural healing where the 170 
epidermis edges were sealed with normal healing tissue.  171 
Figure 2 shows the macroscopic analysis of the ectopic implants in the subcutaneous 172 
layer at different time points. After 7 days of implantation, the scaffold appeared to be 173 
surrounded by fibrous tissue with no evidence of rejection or excessive inflammatory 174 
reaction (Figure 2a). After 14 days (Figure 2b), the wound scar could hardly be 175 
observed, but the implant zone could still be distinguished due to the swelling caused by 176 
the biomaterial presence. No inflammatory or suppuration evidence beyond the 177 
expected reaction have been detected. 178 
After longer implantation periods of 21 (Fig. 2c) and 30 days (Fig. 2d), there was 179 
adequate integration with no foreign body reaction or excessive inflammatory signals. It 180 
is important to note the presence of a vascular network around the scaffold capsule, 181 
which suggested an optimal tissue response for isolation of the foreign material and a 182 
tolerance to drive a slow and clear degradation of this material.  183 
Histology and immunohistochemistry 184 
The optical microscopy studies of the scaffolds that were extracted at different time 185 
points and stained with Hematoxylin-eosin are shown in Figure 3. These histological 186 
studies allow us to observe the evolution over time of the fibrous capsule (FC) formed 187 
around the scaffolds. 188 
Figure 3a shows the microscopy results after 7 days of implantation. At this time, a 189 
fibrous reaction is observed; the scaffold appears surrounded by a thin and loose fibrous 190 
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capsule. The scaffold insertion zone has closed, and the dermis undergoes a healing 191 
process with no evidence of edema formation or presence of inflammatory cells beyond 192 
a normal healing process, which is indicative of an absence of foreign body reaction and 193 
biomaterial rejection. Fibrous tissues with proliferative fibroblastoid cells were 194 
observed within the scaffold pores, whereas several neoformed blood vessels were 195 
detected in the implant periphery around the capsule. These observations are evidence 196 
of excellent integration and biocompatibility of the scaffold (Figure 3a). 197 
After 14 days of implantation (Figure 3b), the biomaterial is still surrounded by a more 198 
fibrous capsule. The input zone has closed, and the dermis is completely healed. The 199 
surrounding tissue has colonized the scaffold by penetration within the macropores, 200 
where fibroblastoid-shaped cells can be observed. This surrounding tissue is extensively 201 
vascularized with several blood vessels around the capsule. The first observation of 202 
material resorption can be detected, especially around the lateral edges where an evident 203 
thickening of the fibrous capsule can be observed.  204 
After 21 days (Figure 3c), the fibrous capsule starts to stabilize; it is thinner, better 205 
organized and more compact than the capsule observed after 14 days. Of note, tissue 206 
scaffold colonization occurred in the macropore zone, and vascularization was observed 207 
in the capsule periphery. These observations suggest that the biomaterial is starting to 208 
become isolated from the subcutaneous tissu  with which it had been intimately in 209 
contact during the earlier study times. The material resorption is still limited, as the 210 
presence of the biomaterial was observed around the lateral edges similar to what was 211 
observed after 14 days. Figure 3d shows the scaffold after 30 days of implantation. The 212 
capsule becomes thicker, more vascularized, and fibrous around the scaffold. The tissue 213 
has completely penetrated within all the macropores, and several cells can be observed 214 
inside the biomaterial. This demonstrates successful integration of the biomaterial into 215 
the biological tissue. We also observed enhanced material resorption. In addition to the 216 
considerable amount of cell colonization in the biomaterial, the absence of edema, 217 
foreign body reaction, or giant cells attacking the biomaterial indicated compatibility 218 
between the material and the surrounding cell tissue. 219 
The results obtained from Sirius Red staining at different implantation time points are 220 
shown in Figure 4. After 7 days, immature collagen (type III) is observed in the implant 221 
area around the biomaterial (Figure 4a). No evidence of mature collagen (type I) is 222 
detected. The samples extracted after 14 days (Figure 4b) show a more fibrous capsule, 223 
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which contains immature collagen, while small zones with collagen type I could be 224 
observed.  225 
Figures 4c shows that after 21 days, the expression of mature collagen has increased, 226 
especially in the lateral edges around the capsule. After 30 days (Figure 4d), the 227 
biomaterial appeared to be completely surrounded by type I mature collagen, especially 228 
in some zones of the capsule near the dermis. 229 
The analysis of collagen expression around and inside the scaffold by 230 
immunohistochemistry techniques shows no evidence of collagen I markers until 30 231 
days after implantation. At this time, the sample shows a slight increase in expression in 232 
some zones of the capsule, specifically those next to the dermis. These observations 233 
confirm the results obtained by Sirius Red staining. 234 
There was no evidence of collagen III expression. At the 14 day time point, there was 235 
barely distinguishable expression in the tissue that had entered into the biomaterial 236 
macropores. However, after 30 days, there is no evidence of this marker.  237 
Immunochemistry characterization was performed using confocal microscopy on the 238 
scaffolds at different time points (Figure 5). The presence of CD4+ cells between 7 and 239 
21 days (Figure 5a and 5b, respectively) is more evident when compared to the presence 240 
of these cells after 30 days (Figure 5c). At 30 days, expression levels of these markers 241 
have decreased, and only a few marked cells can be found within the material. The 242 
observation of CD4+ cells reveals the presence of an inflammatory-type reaction in the 243 
first 20 days after the implantation. After 30 days, this reaction progressively declines, 244 
followed by reabsorption and remodeling of the implant. The location of CD4+ cells 245 
depends on the time after implantation: they are observed on the scaffold periphery 21 246 
days after implantation, while after 30 days, the positive cells are located inside the 247 
scaffold. Analysis of CD8+ cell expression markers (Figure 5 d-f) demonstrated that 248 
hardly any cells were marked after 7 days, while after 21 and 30 days, there was some 249 
evidence of CD8+ expression inside the scaffold.  250 
To determine whether the biomaterial is being degraded and whether a cellular reaction 251 
from the tissue has been triggered, we characterized the expression of the macrophage 252 
marker ED1 at all time points. After 7 and 21 days, there was scarce expression of ED1 253 
in cells located in the capsule area as well as in cells around the material periphery 254 
(Figure 5g-h). However, ED1 expression noticeably increases after 30 days (Figure 5i). 255 
This is in agreement with the histological characterization of these scaffolds, where an 256 
increase in the number of macrophages had been observed. Taken together, our data 257 
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indicate that macrophage presence around the scaffold contributed to the degradation of 258 
the scaffold. 259 
We next observed that Vascular Endothelial Growth Factor (VEGF) expression was 260 
detected after 7 days, and a considerable increase in its expression is observed 21 days 261 
after the implantation (Figure 6). VEGF expression was located mostly in the fibrous 262 
capsule generated around the scaffold, in the subcutaneous tissue edge opposite to the 263 
dermis area. 264 
The highest TRAP expression level was detected after 21 days, and the expression level 265 
at 21 days was much higher than at all other time points. After 30 days, decreased 266 
TRAP expression was observed. TRAP expression is detected in the cells that have 267 
colonized the biomaterial (Figure 7). We then analyzed the expression of the osseous 268 
markers Osteopontin (OPN), RunX2 and Osteocalcin (OC) (Figure 8). Expression 269 
levels of OPN increased only slightly after 7 days. OPN expression is detected in the 270 
tissue area that has penetrated the biomaterial, particularly in the extracellular matrix. 271 
There were no RunX2 expressing cells after 7 days; however, after 14 days, we 272 
observed low levels of expression of RunX2, which were maintained until 30 days after 273 
the implant. RunX2+ cells were detected in the material zone close to the fibrous 274 
capsule. Furthermore, OC expression increased after 21 days. All these markers were 275 
localized in the extracellular matrix cells of the fibrous capsule included in the giant 276 
pores of the scaffold.  277 
Discussion 278 
Apatite and apatite-based biomaterials are excellent candidates for bone repair and 279 
regeneration, since apatite is the mineral component of bone and shows an excellent 280 
bioactivity, biocompatibility and osteoconductivity [31, 32]. However, it is necessary to 281 
analyze the tissue response due to injury at the implantation site. It is also important to 282 
note the tolerance capability of the body for acceptance of the foreign body and for the 283 
control of the immune system. 284 
 In the field of bone tissue engineering, the pore architecture and morphology 285 
(microstructure) of the biomaterials to be implanted are critically important, as the pore 286 
size (percentage and connectivity) is related to bone formation, high viability, very low 287 
mortality and osteoblast proliferation [33]. These material features provide a surface 288 
onto which the cells should adhere and grow, while the pore interconnection facilitates 289 
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the angiogenic process that is important for the efficient distribution of the neoformed 290 
blood vessels within the graft [14, 34].  291 
From a materials perspective, the fabrication method used in this work has allowed the 292 
development of scaffolds with a designed composition and architecture. In vitro studies 293 
previously performed on human Saos-2 osteoblasts [13] showed no toxicity. This 294 
biomaterial allowed the culture of osteoblasts on and around the material without 295 
membrane damage, and no oxidative stress was detected.  296 
In our present work in ectopic implants, the macropores of this material facilitate cell 297 
intrusion and the production of extracellular matrix within the scaffold, in agreement 298 
with results obtained by other studies [35- 37].   299 
This evidence indicates the material degradation of the scaffold while it contributes to 300 
the formation of new tissue. Moreover, it has been demonstrated that the pore 301 
architecture determines the biomaterial surface area, a critical parameter that ensures a 302 
higher surface contact with the surrounding tissues and has a marked influence on the 303 
potential release of different substances from the implanted scaffold [38]. A highly 304 
connected porous structure may result in significant improvement in bone repair [38]. In 305 
our study, the tissue and osteoconduction response obtained for our chosen pore 306 
architecture is in agreement with several studies that determined that the ideal pore size 307 
for tissue engineering applications should be in the 200-900 µm interval [37]. 308 
Therefore, we conclude that the hierarchical pore architecture of the biomaterial studied 309 
based on the combination of macropores and micropores is adequate for the generation 310 
and integration of neoformed blood vessels within the tissue that colonizes it. 311 
Furthermore, other studies suggest that biomaterials based on nano-hydroxyapatite are 312 
excellent candidates for hard tissue engineering and that pore size distribution is critical 313 
for cellular colonization [39]. 314 
Our collagen expression studies reveal that most of the collagen is formed in the capsule 315 
that surrounds the biomaterial; in addition, this collagen can be identified as immature 316 
(type III) [40] after 7 and 14 days of implantation, while at 30 days, the expressed 317 
collagen was identified as type I (mature collagen). 318 
Histological studies confirmed that after 14 days, many neoformed blood vessels were 319 
observed not only around the biomaterial but also passing through its macropores. This 320 
invasion ensures nutrient arrival and waste elimination, thus facilitating cell survival 321 
and new tissue formation. The presence of the blood vessel formation marker VEGF 322 
was detected throughout the study, with maximum expression after 21 days. These 323 
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results agree with previous studies that showed that the subcutaneous implant of 324 
different types of hydroxyapatite-based biomaterials induces the formation of a capsule 325 
composed by fibrous tissue, an enhanced vascularization and the presence of 326 
multinucleated giant cells [36]. Concerning the immune response, the absence of 327 
evident inflammation demonstrates that the scaffold itself, and its degradation products, 328 
are not toxic. These results agree with those obtained by using poly(D,L lactide)/nano-329 
hydroxyapatite composite scaffolds [41] where both neutrophils and lymphocytes 330 
remain in the tissue 9 weeks after the biomaterial implantation.  331 
The presence of CD4 and CD8 positive cells indicates an inflammatory-type reaction in 332 
the first 20 days after the implantation that progressively decreases. Simultaneously, 333 
scaffold resorption and bone remodeling were observed, in agreement with increased 334 
TRAP expression. Cells that express CD4 were found in the tissue surrounding the 335 
material at early stages, thus indicating the usual physiological defense reaction against 336 
the implant. This response is beneficial considering that the activation of the host tissue 337 
by the material is required to trigger the regeneration process. The expression of CD4+ 338 
cells confirms that the nCHA/agarose scaffold activates a mild immune response that 339 
progressively declines over time as can be deduced from the scarce presence of CD4+ 340 
cells after 30 days. On the other hand, the expression of the CD8 marker (cytotoxic 341 
lymphocytes) is low and decreases to close to zero after 21 days. Therefore, we 342 
confirmed that the immune system activation does not induce a rejection reaction 343 
against the implant. The balanced presence of both markers demonstrates an adequate 344 
reaction from the host tissue to the implanted scaffold. Moreover, Anderson et al [42] 345 
argue that the presence of foreign body multinucleated giant cells facilitates the material 346 
resorption process. Thus, we conclude that the material is being resorbed after 14 days, 347 
and cells of this lineage can be detected.  348 
The ED1 marker, specific for rat macrophages, was detected mainly around the scaffold 349 
at all time points studied. Although expression of this marker slightly increased with 350 
time, no uncontrolled macrophage reactions were observed. After 30 days, the scaffold 351 
starts to be gradually resorbed, which agrees with the results of Holzapfel et al [43] for 352 
hydroxyapatite subcutaneous implantations in humans. These authors observed that 353 
after 18 months, residues of the material remained in the implantation site, thus 354 
indicating a slow resorption process. The scarce amount of macrophages observed in 355 
both their work and in the present work, suggests that scaffolds based on hydroxyapatite 356 
are characterized by a slow resorption process and a moderate cell response. 357 
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To ascertain if the material used in this work has osteoconductive properties when 358 
ectopically implanted, different markers of the osteogenic lineage were analyzed 359 
(Figure 8). The low levels of osteopontin expression at all time points suggest that the 360 
scaffold degradation may induce matrix formation, which may increase the osteogenic 361 
differentiation of the progenitor cells coming from the host tissue. In addition, 362 
expression of the TRAP marker is indicative of a remodeling process of the osteoclastic 363 
lineage cells. Furthermore, weak expression of Runx2, an early transcription factor 364 
within the chondrogenic and osteogenic lineages differentiation reaction, has been 365 
detected. In addition, the prominent expression of OC observed is indicative of 366 
osteogenic tissue formation as a consequence of the subcutaneous implantation of the 367 
nCHA/agarose scaffold. 368 
Conclusion 369 
The present work describes the successful use of an ectopic rat model to study the 370 
material resorption and osteoinductive properties of 3D macroporous apatite/agarose 371 
scaffolds. The scaffold used in this work shows a satisfactory biocompatibility when 372 
implanted subcutaneously. After 30 days, the biomaterial starts to be gradually 373 
resorbed, indicating that the material is also biodegradable. Taken together, our data 374 
along with other studies concludes that the proposed scaffold fulfills the biological 375 
requisites of tissue engineering. Histological and immunochemical studies show that the 376 
scaffold is capable of promoting in vivo osteogenesis in ectopic areas. These results 377 
support the usefulness of these apatite/agarose scaffolds as a potential material for 378 
applications in guided bone regeneration. 379 
It must be highlighted that the chemical composition is not the only factor that has a 380 
critical influence on the biocompatibility and biodegradability of these scaffolds. It has 381 
been verified that both the microstructure and the hierarchical pore architecture 382 
facilitate cell colonization, fluid exchange and implant vascularization. 383 
To summarize, we can conclude that 3D nano-apatite/agarose scaffold improves 384 
connective integration while slowing apatite degradation. Thus, this biomaterial would 385 
drive rapid bone mobilization. 386 
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 528 
Figure legends 529 
Figure 1. a) Subcutaneous implant of nCHA/agarose scaffolds in Wistar female rats. 530 
Inset: Macroscopic image of the piece introduced. b) Scanning electron microscopy 531 
image of the piece introduced.  532 
Figure 2. Photographs of the ectopic implant at different time points: a) 7 days, b) 14 533 
days, c) 21 days and d) 30 days. 534 
Figure 3. Microscopic images, at O.M. 5x, of the stained implants (Hematoxylin-Eosin) 535 
at different time points: a) 7 days, b) 14 days, c) 21 and d) 30 days. (S = Skin; FC = 536 
Fibrose Capsule; BV = Blood Vessel; CHA = nCHA/Agarose scaffold). 537 
Figure 4. Microscopic images, at O.M. 10x, of the stained implants (Sirius Red) at 538 
different time points: a) 7 days, b) 14 days, c) 21 and d) 30 days. (FC = Fibrose 539 
Capsule; CHA = nCHA/Agarose scaffold). 540 
Figure 5. Microscopic images, at O.M. 20x, of the implants (Immunofluorescence 541 
staining) at different time points CD4+ cells at a) 7 days, b) 21 days and c) 30 days; 542 
CD4+ cells at d) 7 days, e) 21 days and f) 30 days; ED1+ cells at g) 7 days, h) 21 days 543 
and i) 30 days. 544 
Figure 6. Microscopic images of VEGF immunohistochemical staining (12,5x) at 7 545 
days (a), 14 days (b), 21 days (c), 30 days (d). e) Expression of VEGF+ cells over time 546 
(7-30 days) Data are expressed as the % of cells that are VEGF+. Significant 547 
differences are detected after 21 and 30 days when compared to earlier time points 548 
(*p<0.05). 549 
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Figure 7. Microscopic images of TRAP immunohistochemical staining: a) Negative 550 
control (O.M. 40x); b) 7 days (O.M. 40x); c) 14 days (O.M. 40x); d) 21 days (O.M. 551 
40x); e) 30 days (O.M. 40x); f) Quantification of the percentage of labeled cells at each 552 
time point. There was a significant increase in TRAP levels at 21 days, remaining high 553 
at 30 days (*p<0,05). 554 
Figure 8. a) Expression of markers for angiogenesis (VEGF), osteogenesis (OPN) and 555 
bone remodeling (TRAP) at different time points. (VEGF = Vascular Endothelial 556 
Growth Factor; OPN = Osteopontin; TRAP = Resistant Tartrate Acid Phosphatase). (- = 557 
no expression, 0-10% marked cells; + = slight expression, 10-35%; ++ = moderate 558 
expression, 35-50%; +++ = high expression, > 50%). and Microscopic images of OPN 559 
immunohistochemical staining (12,5x) at 7 days (b), 14 days (c), 21 days (d), 30 days 560 
(e). 561 
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